Atomo Diagnostics (AT1) Q3 2026 earnings summary

Executive summary

• Achieved a transformative Q3 with $814k in revenue, strong sales momentum, and a growing order book, including significant HIV orders for Africa and ANZ.

• Expanded product pipeline with advanced HIV, syphilis, and liver function tests, and secured exclusive global license for a novel liver test.

• US FDA CLIA waiver for Lumos' FebriDx validates Pascal platform and unlocks major US market access.

• Completed a $3 million capital raise, maintaining a debt-free balance sheet and supporting operational expansion.

• Expanded global commercial footprint with new international Pascal supply customers and broader sales channels in Australia, US, Europe, Asia, and Africa.

Financial highlights

• Q3 revenue reached $814k, with year-to-date revenue of ~$3m, up 4% year-over-year.

• Cash receipts for the quarter totaled $1.8 million, including $1.6 million from customers and $165k from grants.

• Cash and cash equivalents at quarter end were $2.6 million, with the company remaining debt-free.

• Operating expenses for the quarter were $1.8 million, with cash outflows totaling $2.6 million, focused on delivery and new product development.

• Balance sheet strengthened by a capital raise at quarter-end, not yet reflected in reported numbers.

Outlook and guidance

• Anticipates transformational growth in Pascal revenues following US FDA CLIA waiver for FebriDx, unlocking significant US market potential.

• EBITDA losses are narrowing, trending toward breakeven as revenue channels expand and new products are commercialized.

• Focus on expanding the test portfolio, including syphilis and liver function tests, leveraging existing HIV infrastructure for rapid market entry.

• No specific net profit timeline, but confident in the path to profitability.

• Anticipate continued growth in HIV testing sales for at least 5–10 years.